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Abstract: The West Nile virus (WNV) is an emerging infection of biodefense concern and 
there are no available treatments or vaccines. Here we used a high-throughput method 
based on a novel gene expression analysis, RNA-Seq, to give a global picture of 
differential gene expression by primary human macrophages of 10 healthy donors infected 
in vitro with WNV. From a total of 28 million reads per sample, we identified 1,514 
transcripts that were differentially expressed after infection. Both predicted and novel gene 
changes were detected, as were gene isoforms, and while many of the genes were 
expressed by all donors, some were unique. Knock-down of genes not previously known to 
be associated with WNV resistance identified their critical role in control of viral infection. 
Our study distinguishes both common gene pathways as well as novel cellular responses. 
Such analyses will be valuable for translational studies of susceptible and resistant 
individuals—and for targeting therapeutics—in multiple biological settings.  
Keywords: anti-viral gene expression; immune response; macrophage; RNA-Seq; 
West Nile virus 
 
1. Introduction 
West Nile virus (WNV) is a mosquito-borne enveloped positive-strand RNA virus belonging to the 
family Flaviviridae, which includes yellow fever and dengue viruses [1]. From 1999–2012, 37,088 
cases were reported to the Centers for Diseases Control, including 1,549 fatalities, with the estimated 
number of people infected approaching three million [2–4]. WNV infections in healthy humans are 
typically asymptomatic, but severe symptoms—more common in older patients (>55 years old)—
including mengingoencephalitis and death [2,3]. The immune response to WNV is multifactorial 
including critical roles for both adaptive [5–8] and innate immune responses [9]. Mice depleted of 
macrophages, neutrophils, or lacking key components of innate immunity exhibit higher and extended 
viremia and increased mortality to infection with WNV [9–11].  
The ability to profile the transcriptome of eukaryotic cells has led to the identification of key 
components that undergo alterations during diverse biological processes. For example, the profiling 
of  gene expression in different leukemias has led to the classification of distinct subclasses of 
disease  [12]. Recent advances in technology include an RNA sequencing method (RNA-Seq) that 
involves the direct sequencing of cDNA for monitoring quantitative gene expression [13–20].   
RNA-Seq has at least an 8,000 fold dynamic range, and can follow expression at the level of an 
individual gene, exon and particular splice isoforms, eliminating the need for array design. Here we 
have used this method to identify the gene expression program of primary human immune cells in 
response to infection with WNV. We have identified both common and unique responses to viral Viruses 2013, 5  1666 
 
infection as well as components linked to successful resistance to infection that may be targets 
for therapeutics.  
2. Results and Discussion 
2.1. RNA-Seq Analysis of Differential Gene Expression by Human Macrophages Infected with WNV 
To follow the level of expression of host genes that change during flaviviral infection, samples of 
primary human macrophages from 10 healthy donors were infected in vitro with virulent WNV (strain 
CT 2741, MOI = 1) for 24 hours [21]. Q-PCR confirmed elevated expression of mRNA for IL-8, 
expected in response to WNV infection, as well as of WNV E gene, reflecting the level of viral RNA 
(data not shown). PolyA+ RNA was prepared from uninfected and WNV-infected primary 
macrophages, fragmented, and subjected to sequencing using the Illumina Genome Analyzer 2. 
Approximately 28 million quality filtered 36 nt long reads were obtained from each sample. About 
88% of reads were mapped to the human genome using TOPHAT [22], suggesting good quality of 
RNA-seq (Supplementary Table S1). Genes and transcripts were scored for expression by a maximum 
likelihood based method implemented in Cufflinks [23].  
Variation between human subjects may reveal distinct yet effective anti-viral mechanisms used by 
different subjects when responding to infection with WNV. Thus we sought to identify both common 
and individual-specific changes in the anti-viral gene program. We compared the normalized 
expression levels from control uninfected and WNV-infected macrophage by performing both pairwise 
and joint comparisons to detect differentially expressed transcripts. Both methods identified a 
consistent set of differentially expressed genes. The first method compares each control/infected 
sample pair using fold change adjusted by using trimmed-mean normalization [24]. A total 
of  732  transcripts showed 4-fold or greater change after infection with WNV consistently across 
all 10 individuals (Supplementary Table S2). When comparing the fold change vs. the expression level 
for our 10 biological uninfected and infected sample pairs, we noted both upregulation and 
downregulation of transcripts that reached greater than 4 fold (Figure 1a). The pattern of differential 
expression of transcripts was similar across all 10 donors suggesting that the anti-viral program 
includes an essential cluster of regulated genes. These include well-characterized responses such as 
type I interferons and chemokines and chemokine receptors [25] as well as less well characterized targets.  
Of note, individuals may have unique mechanisms for anti-viral responses and our initial analysis 
would not identify differentially expressed transcripts detected for some individuals but not others. To 
achieve higher statistical power in analysis of our samples, we combined information from subject 
samples simultaneously and compared the 10 control/10 infected sample pairs jointly using a Bayesian 
hierarchical mixture model to identify differentially expressed transcripts [26]. This newly developed 
algorithm adopts a Poisson-Gamma model for paired expression counts to account for individual 
variation. The expression difference (fold change) is modeled by a mixture of two component 
distributions, one for equal expression and the other for differential expression. Parameter space and 
posterior probability of being differentially expressed are explored using Markov Chain Monte-Carlo 
(MCMC). When this approach was applied to the full collection of 10 sample pairs using the posterior 
probability cutoff 0.5, we detected 1,514 transcripts with differential expression between the control 
uninfected and WNV-infected samples (Supplementary Table S3). This collection of transcripts Viruses 2013, 5  1667 
 
identified includes 505 of the 732 transcripts detected by the individual pair analysis and a wealth of 
additional transcripts (1,009) that may provide critical insight into anti-viral pathways. For a global 
perspective on gene regulation during WNV infection, a heat map of 1,514 differentially expressed 
transcripts was generated using hierarchical clustering analysis (Figure 1b). Our approach identifies 
differentially expressed genes at a lower false discovery rate and successfully detects transcripts with 
high differences after infection even if overall expression levels are low. The Bayesian analysis can 
also identify a transcript that shows a large difference across a majority of individuals while a few 
individuals show no difference. The magnitude of the fold change can differ individual by individual. 
This paired analysis allows sufficient analytic depth to identify transcriptional changes that may 
represent an uncommon anti-viral response pathway, which can be subjected to additional studies to 
clarify pathogenetic mechanisms. 
In addition to identifying differentially expressed transcripts, the depth of the RNA-seq datasets can 
identify changes at the isoform/splicing level of individual genes [19]. In this analysis, we have 
detected 1,514 transcripts corresponding to 1,148 unique genes of which 366 (23%) were found to 
have >1 isoform. This powerful analysis demonstrates the pattern of over or under expression for both 
consistent and unique features of the macrophage anti-viral program. 
Figure 1. Differential gene expression of human macrophages infected with West Nile 
virus (WNV). (a) MA plots of RNA-seq data. The M (log fold change) of each transcript 
between mock and infected pair is plotted against A (average log concentration/expression 
level) of each mock and infected pair. In these plots, each point represents an annotated 
transcript. The black dots reflect no change and the red dots represent transcripts with  
4-fold change by edgeR analysis. The straight lines in each plot reflect zero expression in 
one condition and nonzero expression in the other condition. (b) Heatmap for 1,514 
differentially expressed transcripts (Bayesian DE paired analysis) in human macrophages 
infected with WNV using hierarchical clustering analysis. Red, black and green colors 
indicate gene expression above, equal to and below the mean, respectively, for   
subjects #1–10.  
a 
 Viruses 2013, 5  1668 
 
Figure 1. Cont. 
b 
 
2.2. Virally Induced Pathways Identified by Functional Annotation Clustering 
To determine the cellular effects of these differentially expressed gene transcripts, we conducted 
functional annotation clustering analysis using DAVID, an on-line functional annotation tool for gene 
enrichment analysis [27,28]. The list of ENSEMBL transcript IDs corresponding to these differentially 
expressed genes mapped to 929 DAVID IDs [29]. The functional annotation analysis of the 
top 8 clusters, all with an enrichment score ≥5.24, reflects an active anti-viral gene expression program 
including the genes that were detected to be commonly up- or down-regulated in response to in vitro 
WNV-challenge (Table 1). Cluster 1 (DAVID enrichment score: 20.92) primarily consists of genes 
that are involved in the regulation of defense and immune response. The second functional annotation 
cluster (DAVID enrichment score: 9.21) includes genes related to immune cell activation, cluster 3 
(DAVID enrichment score: 6.62) and cluster 4 (DAVID enrichment score: 6.40) consists of genes with 
known functions in cytokine and chemokine production. Additional clusters 5–8 identify molecular 
functions of genes associated with a more generalized apoptosis, cell death, and signal transduction. 
The induction of apoptosis by WNV, which regulates pro-inflammatory responses, has been previously 
reported in cell lines and neuronal cell types and may be mediated by induction of regulatory 
miRNA [30–32]. The functional cluster analysis was similar when we analyzed the 1,009 transcripts 
identified only using the Bayesian method; these were enriched to immune response categories 
reflecting an active anti-viral gene expression program (data not shown).  
While the majority of differentially expressed genes showed an increase on infection with WNV, 
293 of the 1,514 transcripts were detected to be down-regulated (19.4%). The down-regulated 
transcripts were enriched in functional clusters involved in intracellular organelle and membrane 
transport functions in the samples infected with WNV. Notably, the sensitivity provided by the model 
also allows identification of rare differentially expressed transcripts in only a few donors for which 
determining functional significance will require further investigation.  Viruses 2013, 5  1669 
 
Table 1. Results of functional annotation clustering.  
Category Term  Count  PValue  FDR 
Cluster 1  Enrichment Score: 20.92 
GO: BP  GO:0006952~defense response  101  2.50 × 10
−25 4.53  ×  10
−22 
GO: BP  GO:0006954~inflammatory response  64  3.66 × 10
−20 6.64  ×  10
−17 
GO: BP  GO:0009611~response to wounding  83  1.80 × 10
−19 3.27  ×  10
−16 
Cluster 2  Enrichment Score: 9.21 
GO: BP  GO:0001775~cell activation  46  2.83 × 10
−11 5.13  ×  10
−8 
GO: BP  GO:0045321~leukocyte activation  40  2.67 × 10
−10 4.84  ×  10
−7 
GO: BP  GO:0046649~lymphocyte activation  34  3.07 × 10
−9 5.57  ×  10
−6 
GO: BP  GO:0042110~T cell activation  26  6.22 × 10
−9 1.13  ×  10
−5 
Cluster 3  Enrichment Score: 6.62 
SP_PIR_KEYWORDS  inflammatory response  26  4.45 × 10
−15 6.43  ×  10
−12 
SP_PIR_KEYWORDS chemotaxis  22  7.21  ×  10
−12 1.04  ×  10
−8 
GO: MF  GO:0005125~cytokine activity  37  2.14 × 10
−11 3.31  ×  10
−8 
SP_PIR_KEYWORDS cytokine  33  7.05  ×  10
−11 1.02  ×  10
−7 
GO: MF  GO:0042379~chemokine receptor binding  18  1.62 × 10
−10 2.50  ×  10
−7 
INTERPRO  IPR001811:Small chemokine, interleukin-8-like  16  3.86 × 10
−10 6.24  ×  10
−7 
GO: MF  GO:0008009~chemokine activity  17  5.38 × 10
−10 8.32  ×  10
−7 
SMART SM00199:SCY  16  2.96  ×  10
−9 3.89  ×  10
−6 
KEGG_PATHWAY hsa04060:Cytokine-cytokine receptor interaction  44  4.30 × 10
−9 5.16  ×  10
−6 
SP_PIR_KEYWORDS inflammation  12  5.28  ×  10
−9 7.64  ×  10
−6 
GO: BP  GO:0006935~chemotaxis  27  2.20 × 10
−7 3.99  ×  10
−4 
GO: BP  GO:0042330~taxis  27  2.20 × 10
−7 3.99  ×  10
−4 
GO: CC  GO:0005615~extracellular space  65  2.68 × 10
−7 3.73  ×  10
−4 
KEGG_PATHWAY  hsa04062:Chemokine signaling pathway  32  5.92 × 10
−7 7.10  ×  10
−4 
GO: BP  GO:0007626~locomotory behavior  35  2.35 × 10
−6 4.26  ×  10
−3 
PIR_SUPERFAMILY  PIRSF001950:small inducible chemokine, C/CC types  9  1.28 × 10
−5 1.78  ×  10
−2 
INTERPRO  IPR000827:Small chemokine, C-C group, conserved site  9  1.66 × 10
−5 2.68  ×  10
−2 
Cluster 4  Enrichment Score: 6.40 
GO: BP  GO:0001817~regulation of cytokine production  33  1.03 × 10
−9 1.86  ×  10
−6 
GO: BP 
GO:0051240~positive regulation of multicellular 
organismal process 
32 3.97  ×  10
−6 7.21  ×  10
−3 
GO: BP  GO:0001819~positive regulation of cytokine production  17  1.47 × 10
−5 2.67  ×  10
−2 
Cluster 5  Enrichment Score: 6.32 
GO: BP  GO:0002237~response to molecule of bacterial origin  20  6.81 × 10
−8 1.24  ×  10
−4 
GO: BP  GO:0034097~response to cytokine stimulus  19  9.11 × 10
−8 1.65  ×  10
−4 
GO: BP  GO:0032496~response to lipopolysaccharide  18  3.37 × 10
−7 6.11  ×  10
−4 
GO: BP  GO:0009617~response to bacterium  26  2.43 × 10
−5 4.41  ×  10
−2 
Cluster 6  Enrichment Score: 5.95 
GO: BP  GO:0042981~regulation of apoptosis  87  1.03 × 10
−10 1.86  ×  10
−7 
GO: BP  GO:0043067~regulation of programmed cell death  87  1.65 × 10
−10 3.00  ×  10
−7 
GO: BP  GO:0010941~regulation of cell death  87  1.99 × 10
−10 3.61  ×  10
−7 
GO: BP  GO:0043065~positive regulation of apoptosis  48  1.20 × 10
−6 2.18  ×  10
−3 
GO: BP 
GO:0043068~positive regulation of programmed cell 
death 
48 1.46  ×  10
−6 2.65  ×  10
−3 
GO: BP  GO:0010942~positive regulation of cell death  48  1.67 × 10
−6 3.03  ×  10
−3 
GO: BP  GO:0006916~anti-apoptosis  27  2.66 × 10
−5 4.82  ×  10
−2 
GO: BP  GO:0006917~induction of apoptosis  36  2.75 × 10
−5 4.98  ×  10
−2 Viruses 2013, 5  1670 
 
Table 1. Cont. 
Category Term  Count  PValue  FDR 
Cluster 7  Enrichment Score: 5.33 
GO: BP 
GO:0002684~positive regulation of immune system 
process 
42 1.05  ×  10
−11 1.91  ×  10
−8 
GO: BP  GO:0050865~regulation of cell activation  29  1.06 × 10
−7 1.92  ×  10
−4 
GO: BP  GO:0002694~regulation of leukocyte activation  28  1.26 × 10
−7 2.29  ×  10
−4 
GO: BP  GO:0051249~regulation of lymphocyte activation  26  1.75 × 10
−7 3.17  ×  10
−4 
GO: BP 
GO:0050671~positive regulation of lymphocyte 
proliferation 
15 5.79  ×  10
−7 1.05  ×  10
−3 
GO: BP 
GO:0032946~positive regulation of mononuclear cell 
proliferation 
15 7.35  ×  10
−7 1.33  ×  10
−3 
GO: BP  GO:0070665~positive regulation of leukocyte proliferation  15  7.35 × 10
−7 1.33  ×  10
−3 
GO: BP  GO:0050867~positive regulation of cell activation  21  1.04 × 10
−6 1.88  ×  10
−3 
GO: BP  GO:0050670~regulation of lymphocyte proliferation  18  1.04 × 10
−6 1.89  ×  10
−3 
GO: BP  GO:0032944~regulation of mononuclear cell proliferation  18  1.24 × 10
−6 2.26  ×  10
−3 
GO: BP  GO:0070663~regulation of leukocyte proliferation  18  1.24 × 10
−6 2.26  ×  10
−3 
GO: BP  GO:0002696~positive regulation of leukocyte activation  20  2.08 × 10
−6 3.78  ×  10
−3 
GO: BP  GO:0051251~positive regulation of lymphocyte activation  19  2.30 × 10
−6 4.17  ×  10
−3 
GO: BP  GO:0050863~regulation of T cell activation  20  9.40 × 10
−6 1.71  ×  10
−2 
Cluster 8  Enrichment Score: 5.24 
GO: BP 
GO:0043122~regulation of I-kappaB kinase/NF-kappaB 
cascade 
21 5.63  ×  10
−7 1.02  ×  10
−3 
GO: BP 
GO:0043123~positive regulation of I-kappaB 
kinase/NF-kappaB cascade 
19 2.30  ×  10
−6 4.17  ×  10
−3 
GO: BP  GO:0010647~positive regulation of cell communication  39  3.50 × 10
−6 6.36  ×  10
−3 
GO: BP  GO:0010740~positive regulation of protein kinase cascade  25  5.99 × 10
−6 1.09  ×  10
−2 
2.3. Correlation of Gene Expression Changes with Genome-Wide RNAi Analysis 
We have further classified our results from RNA-Seq in light of our recent genome-scale RNA 
interference (RNAi) screen for human genes associated with WNV infection [33]. This 
high-throughput study silenced 21,121 human genes in HeLa cells and provided the first 
comprehensive picture of the molecular interactions of WNV with human cells. RNAi has proven 
informative for studies of HIV and hepatitis C virus as well [34,35]. RNAi identified human cellular 
factors facilitating WNV infection including several known host factors of WNV infection 
(e.g., endosomal proton pump vATPase) and 294 host targets that have not previously been associated 
with WNV infection, defined as host susceptibility factors (HSF) and host resistance factors 
(HRF) [33]. When we calculated the average expression in each RNA-Seq sample of ~200 HSF and 
~13 HRF as defined in the RNAi study, we found that for each subject, average HSF expression 
increases and average HRF expression decreases after infection (Figure 2). Further, we identified 13 
HSFs and 2 HRFs from HeLa cells that are also differentially expressed in RNA-Seq analysis of 
human macrophages and likely represent important elements in the anti-viral gene program 
(Supplementary Table S4). While the magnitude of effect varied between donors, the overall gene 
changes are quite consistent. This suggests that viral infection is a powerful stimulus that may redirect Viruses 2013, 5  1671 
 
host gene expression to create an environment that is more conducive to the virus, a common viral 
strategy to promote replication and survival. 
Figure 2. Correlation of WNV infection with change in expression of genes identified by 
genome-wide RNAi screen.  Plot represents average expression (FPKM) of ~180 host 
susceptibility factors (HSF) genes in mock () and ~13 host resistance factors (HRF) genes 
() samples with uninfected samples shown in open symbols. For all 10 samples, the 
average expression (FPKM) of HSF genes increases while the average expression of HRF 
genes decreases from mock to infected samples. 
 
2.4. RNAi Knockdown of Novel Genes Shows Critical Role in Resistance to WNV Infection  
To dissect mechanisms of the anti-viral program in human macrophages, we further assessed a 
group of genes identified here by RNA-Seq. We have previously shown that knockdown of specific 
targets in primary macrophages can modulate efficiency of WNV infection and modify anti-viral 
responses [21]. To assess the role of differentially expressed genes identified by RNA-Seq analysis, 
siRNA duplexes corresponding to target genes were used to knockdown levels of the target protein in 
primary macrophages prior to infection with WNV. Target genes were selected which were common 
to all 10 donors and not previously known to be associated with macrophage response to WNV 
infection. The 732 common transcripts that were significantly differentially expressed by all 10 donors 
correspond to 564 unique genes (Supplementary Table S2), which we further characterized by 
functional annotation clustering analysis using DAVID. The molecular function of these genes is 
primarily characterized by their cytokine activity (GO:0005125, 11.4%), which is supported by the 
finding that genes associated with the “Cytokine-cytokine receptor interactions” (KEGG:hsa04060, 
12.2%) were found to be over-represented in the sample list as compared to the background of the 
whole human genome. Enriched cluster contains additional KEGG pathway associated genes, most 
notably the pathways for “Toll-like receptor signaling” (KEGG:04620, 6.9%), “Cytosolic DNA-sensing” 
(KEGG:hsa04623, 5.3%) and the pathway for “RIG-I-like receptor signaling” (KEGG:hsa04622, 
5.8%). This observation supports the expectation that an in vitro WNV challenge of macrophages 
obtained from healthy donors triggers a strong anti-viral response. Since the enriched genes in these 
pathways are type I IFN and chemokines, two interferon-stimulated genes and two chemokine Viruses 2013, 5  1672 
 
receptors were selected for RNAi knockdown. The targets selected were IFI27 (interferon alpha-
inducible protein 27), AIM2 (absent in melanoma 2), CCR3 (receptor of chemokines CCL5 and 
CCL8), and CXCR3 (receptor of chemokine CXCL10), which is essential for control of WNV 
infection in the central nervous system [36]. When we quantified expression of these targets by 
Q-PCR, each target gene, IFI27, AIM2, and CCL5, CCL8, and CXCL10—ligands for CCR3 and 
CXCR3—was upregulated in all 10 samples as confirmed by Q-PCR (average fold upregulation for 
IFI27, 133 fold; AIM2, 476 fold; CCL5, 249 fold; CCL8, 2724 fold; and CXCL10, 22772 fold; range 
p = 0.03–p = 0.008). Each of the genes was silenced efficiently as quantified by Q-PCR using gene 
specific primers; gene expression was determined after 48 h of infection with WNV and was decreased 
to 10%–20% of levels in non-targeting siRNA transfected control cells (Figure 3a). siRNA treated 
macrophages were infected with WNV and the viral load was determined by Q-PCR of the WNV 
envelope gene (E) at 48 h when detection of viral replication is maximal (Figure 3b). Of note, RNAi 
knockdown of each target resulted in increased viral load, suggesting increased efficiency of viral 
infection, and an important role for these proteins (or others they may affect) in resistance to infection 
with WNV. The identification of these genes through RNA-Seq and validation through knockdown 
studies has demonstrated their previously unrecognized role in control of WNV infection.  
Figure 3. Effect of RNAi knockdown on WNV infection. Primary macrophages from 
healthy volunteers were transfected using the Nucleofection technology with siRNA 
targeting the genes shown and a non-targeting (nt) control siRNA. (a) The efficiency of 
RNAi knockdown after 48 h of infection with WNV was assessed via qPCR of target 
gene/actin compared with non-targeting control cells which was defined as 100% 
expression (n = 3). (b) WNV burdens in human macrophages after RNAi silencing. 
After 36 h of transfection, macrophages were infected with WNV (MOI = 1) for 48 h and 
viral load was quantified by qPCR. Data shown are the means ± SEM (*p < 0.05, 
** p < 0.01, ***p < 0.001, T-test). Representative results from at least three independent 
experiments with successful RNAi silencing (>70%).  
 Viruses 2013, 5  1673 
 
3. Experimental Materials and Methods 
3.1. Blood Donors and Preparation of Cells 
Heparinized blood from healthy volunteers was obtained with written informed consent under an 
approved protocol of the Human Investigations Committee of Yale University School of Medicine. 
Donors had no acute illness, took no antibiotics or non-steroidal anti-inflammatory drugs [37]. Donors 
(n = 10) were aged 27.7 ± 3.9 years (range 22–36), 40% female and all were white. Peripheral blood 
mononuclear cells (PBMCs) were isolated using Ficoll-Hypaque (GE Healthcare, NJ, USA) and 
suspended in RPMI-1640 containing L-Glutamine supplemented with 20% (v/v) human serum (Lonza, 
MD, USA), 100 U/mL penicillin and 100 µg/mL streptomycin (Invitrogen, CA, USA). Cells were 
plated at 2 × 10
7 cells/10 cm tissue culture dish. Non-adherent cells were washed away after 2 h, and 
adherent monocytes were incubated 6–8 days to mature into macrophages [21].  
3.2. WNV Strains and Infections 
Virulent WNV (CT-2741) was generously provided by Dr. John Anderson, Connecticut 
Agricultural Experiment Station, New Haven, CT, USA [38] and was passaged once in Vero cells 
(ATCC CCL-81) and viral PFU were quantified by plaque assays [21]. WNV studies were conducted 
in a Biosafety Level 3 facility, licensed by the State of Connecticut and Yale University. Cells were 
infected with WNV (multiplicity of infection, MOI = 1) for 24 h. Under these conditions, viral 
infection results in infection of 80%–90% of macrophages by 12 h as quantified by immunofluorescent 
staining using a monoclonal antibody directed against WNV E protein [21].  
3.3. RNA Interference 
Adherent monocyte-derived macrophages were dislodged using Trypsin/EDTA solution 
(0.5 mg/mL trypsin and 0.2 mg/mL EDTA in PBS) for 30 min at room temperature. Macrophages  
(2 × 10
6) were transfected with 2 µM of small interfering RNAs (siRNAs) targeting IFI27, AIM2, 
CCR3 or CXCR3 (Dharmacon, CO, USA), using the nucleofection technology (Amaxa, MD, USA). 
Cells transfected with non-targeting siRNAs will be used as a control. Transfected cells were 
incubated for 36 h before infection studies.  
3.4. Quantitative Polymerase Chain Reaction (qPCR) 
Total RNA was harvested from infected and uninfected macrophages using the RNeasy mini kit 
(Qiagen, MD, USA), and cDNA was synthesized using AffinityScript Multi Temperature cDNA 
Synthesis Kit (Stratagene, CA, USA) according to standard protocols. Amplification was performed in 
an iCycler (Bio-Rad, CA, USA) for 60 cycles with an annealing temperature at 60 °C and values were 
normalized to β-actin. Primers and probes for qPCRs were from Dharmacon or synthesized according 
to customized sequences as follows: WNV-E (forward: 5'- TTC TCG AAG GCG ACA GCT G-3', 
reverse: 5'- CCG CCT CCA TAT TCA TCA TC-3', probe: FAM ATG TCT AAG GAC AAG CCT ACC 
ATC TAMRA) and β-actin (forward: 5'-ATC CTG GCCTCG CTGTCCAC-3', reverse: 5'- GGG CCG 
GAC TCG TCA TAC-3', probe: FAM TCC AGC AGA TGT GGA TCA GCA AGC A TAMRA) [39].  Viruses 2013, 5  1674 
 
3.5. Preparation of Libraries for Illumina Deep-Sequencing 
mRNA was fragmented into 150–300 bp fragments by incubation in RNA Fragmentation Reagent 
(Ambion, TX, USA) at 70 °C for 5 minutes. The fragmented mRNA was purified away from the 
fragmentation buffer by Agencourt RNAClean beads (Beckman Coulter, MA, USA) following 
manufacturer’s instructions. The purified, fragmented mRNA was converted into double-stranded 
cDNA using the SuperScript Double-Stranded cDNA Synthesis Kit (Invitrogen, CA, USA) by priming 
with random hexamers. cDNA libraries were prepared for Illumina deep-sequencing as previously 
described [13]. 36 nucleotides of sequence were determined from one end of each cDNA fragment 
using high throughput DNA sequencing [40]. The RNA-Seq raw data files have been deposited in 
NCBI’s Gene Expression Omnibus (GEO) and are accessible through GEO Series accession number 
GSE40718 [41,42].  
3.6. RNA-Seq Analysis 
Hi-Seq sequence data from 10 donors (mock or WNV infected) was processed to obtain estimates 
expression level of genes and transcripts. Using the fastq files, all sequencing reads were mapped back 
to human genome (hg19) using default setting of TopHat (v1.1.4) [22]. Cufflinks (v0.9.3) [43], was 
used to assemble the mapped reads against the ENSEMBL (release 57) gene structure annotation, and 
estimate expression levels for each transcript [23], and was not allowed to modify the gene 
annotations. To estimate isoform-level abundances, Cufflinks uses a probabilistic model of paired-end 
sequencing to derive a likelihood for the abundance of transcripts to calculate ambiguous isoforms. To 
analyze the gene expression of human macrophages we first converted the estimated expression levels 
in FPKM unit (# reads × 10
9/transcript length/library) to pseudocounts (# of reads originated from each 
transcript isoform). The effective transcript length reported by Cufflinks is used for the conversion. 
The pseudocounts were further normalized across samples using the trimmed mean of M-values 
(TMM) method [44]. Differentially expressed transcripts were identified using edgeR and 
Bayesian  DE paired analysis. Transcripts were excluded if <10 in paired conditions or expressed   
in ≤5 subjects. The resulting transcript set was 36,409 transcripts. To be considered differentially 
expressed, a transcript may be present in either mock or WNV-infected samples.  
For the functional annotation clustering, the 1,514 differentially expressed transcripts were 
submitted for analysis using the DAVID web server [29]. The “Medium” default settings were used for 
classification stringency. The functional annotation clustering is based on the occurrence of annotation 
terms e.g., Gene Ontology (GO) [45] in the list of sample genes as compared to the occurrence of these 
terms in the “background” or “population”. The known annotations for the entire human genome  
in the categories “GO—Biological Process”, “GO—Cellular Component”, “GO—Molecular Function”, 
“SP_PIR_KEYWORDS”, “PIR_SUPERFAMILY”, “INTERPRO”, “SMART” and “KEGG pathways” 
were selected as background [46]. 
4. Conclusions 
We have employed RNASeq to provide a comprehensive identification of the critical elements in 
the host innate immune response to infection with WNV. In contrast to microarray experiments, which Viruses 2013, 5  1675 
 
use pre-defined oligonucleotide probes for measuring differential expression of genes, RNA-Seq as 
used in this experiment does not introduce a selection bias in terms of the background or gene 
population. The abundant gene transcripts identified through RNASeq require high level 
bioinformatics analysis and our analysis achieves higher statistical power through combination of 
samples. To evaluate both common gene pathways as well as novel cellular responses will be essential, 
as we examine differences between susceptible and resistant individuals in the population.  
In our analysis we have shown both predicted and novel gene changes in response to infection with 
WNV. Several targets identified here as differentially expressed on infection with WNV are common 
host factors—such as the IFITM proteins—that similarly mediate cellular resistance to other viruses 
including influenza A virus and dengue virus [47]. The interferon (IFN) response is an essential host 
defense program that limits viral infection and was shown here with the upregulation of many 
interferon-inducible genes including MX1, OAS1. These targets are of particular interest as recent 
genomic studies have identified polymorphisms in OAS1 and MX1 that are associated with increased 
risk of symptomatic WNV infection [9,48,49]. Similarly, chemokines and chemokine receptors have 
been shown to be important in control of WNV infection [11,50]. In humans, a 32-bp deletion in the 
coding region of the CC chemokine receptor 5 (CCR5Δ32) was reported to be associated with both 
increased susceptibility to WNV infection and death [51,52], and in mice, CXCR3 and its ligand 
CXCL10 are required for T cell-mediated clearance of WNV primarily within the cerebellum during 
WNV encephalitis [36]. In this study, we demonstrate upregulation of chemokines CCL5 and CCL8 
after WNV infection, and increased viral load following RNAi knockdown of their receptor CCR3, 
confirming generally accepted roles in control of WNV infection. We also detected an increase in 
expression of TLR3 at 24 h, even though TLR3 is dramatically down regulated in macrophages of 
young donors at 3 h, suggesting a dynamic regulation of TLR3 in response to WNV [21]. 
In addition, we have identified a large number of genes not previously associated with WNV 
responses. One such gene identified here, IFI27, is a mitochondrial protein that sensitizes cells to 
apoptotic stimuli via mitochondrial membrane destabilization [53]. Its identification suggests a novel 
mechanism of pathogenesis of WNV infection involving a role for pro-apoptotic signaling and a 
potential avenue for intervention. Our analysis also identified the involvement of several pathways for 
which a role in the host response to WNV had not been fully investigated, including the activation of 
inflammasome signaling. We observed downregulation of NLRP1 and NLRC4 and upregulation of 
NLRP3 and AIM2 during WNV infection. AIM2 is a cytosolic DNA receptor that forms an 
inflammasome with ASC to trigger caspase 1 activation [54] for which a role in RNA virus infection 
was unknown. A role for inflammasomes in WNV infection has recently been described in a murine 
model [55]. The increased viral load shown after RNAi knockdown of AIM2 in this study suggests an 
important role for AIM2 in control of WNV infection.  
To build a model of the key signaling pathways modulated by WNV infection, we focused on 
functional annotation of pathways with many differentially regulated genes identified by our analysis, 
such as viral sensing pathways including TLR and RLR, which recognize specific pathogen associated 
molecular patterns (PAMPs) and initiate signal transduction pathways (Figure 4). Our model includes 
upregulation of key WNV recognition receptors such as TLR3, TLR7, MDA5 and RIG-I, which are 
known to control WNV infection in mouse models [56]. Similarly, we demonstrate upregulation of 
many cytokines, chemokines, including type 1 interferon and proinflammatory cytokines, and their Viruses 2013, 5  1676 
 
receptors and signaling pathways which well-characterized roles in anti-WNV responses [57,58]. Our 
analysis also highlights additional key cellular components including the activation of the autophagy 
and apoptosis pathways. The autophagy machinery can be used to deliver viral genetic material to 
endosomal TLRs for efficient induction of type I interferon and has been linked to diverse aspects of 
innate and adaptive immunity [59]. Many viruses encode proteins that can inhibit apoptosis [60] and 
the triggering of apoptosis has been noted in WNV-infected neuronal tissue [61], but details of the 
roles for autophagy and apoptosis in WNV pathogenesis in innate immunity are not fully understood. 
Finally, when we incorporated WNV proteins that directly associate with these pathways into the 
model, we observed that the virus can target diverse signaling pathways through both physical   
and regulatory interactions. This observation emphasizes the regulation and counter-regulation   
between host and virus. This method should prove valuable for translational studies of resistant and  
susceptible populations, or responders and non-responders—and for targeting therapeutics—in 
multiple biological settings. 
Figure 4. Key signaling pathways modulated by WNV infection. Genes within selected 
pathways identified in the RNAseq analysis were placed on the map using annotation 
information from Gene Ontology, KEGG Pathway, Biocarta Pathway, PANTHER and 
Reactome. Transcriptional regulation in response to WNV in human macrophages is 
indicated by boxes (black, unchanged; red increase in gene expression; blue for decreased 
expression). Interactions between WNV proteins and host components are based on 
previous reports and are shown in grey.  
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